IL218426A0 - Mglur4 allosteric allosteric potentiators, compositions, and methods of treating neurological dysfunction - Google Patents
Mglur4 allosteric allosteric potentiators, compositions, and methods of treating neurological dysfunctionInfo
- Publication number
- IL218426A0 IL218426A0 IL218426A IL21842612A IL218426A0 IL 218426 A0 IL218426 A0 IL 218426A0 IL 218426 A IL218426 A IL 218426A IL 21842612 A IL21842612 A IL 21842612A IL 218426 A0 IL218426 A0 IL 218426A0
- Authority
- IL
- Israel
- Prior art keywords
- allosteric
- compositions
- methods
- mglur4
- potentiators
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title 2
- 101150025480 Grm4 gene Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009251 neurologic dysfunction Effects 0.000 title 1
- 208000015015 neurological dysfunction Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24003109P | 2009-09-04 | 2009-09-04 | |
| PCT/US2010/048030 WO2011029104A1 (en) | 2009-09-04 | 2010-09-07 | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218426A0 true IL218426A0 (en) | 2012-04-30 |
Family
ID=43649686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218426A IL218426A0 (en) | 2009-09-04 | 2012-03-01 | Mglur4 allosteric allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8779157B2 (enExample) |
| EP (1) | EP2473055A4 (enExample) |
| JP (1) | JP2013503909A (enExample) |
| CN (1) | CN102740699A (enExample) |
| AU (1) | AU2010289281A1 (enExample) |
| BR (1) | BR112012004919A2 (enExample) |
| CA (1) | CA2773038A1 (enExample) |
| IL (1) | IL218426A0 (enExample) |
| IN (1) | IN2012DN02580A (enExample) |
| RU (1) | RU2012114770A (enExample) |
| SG (1) | SG178999A1 (enExample) |
| WO (1) | WO2011029104A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8658650B2 (en) | 2009-01-28 | 2014-02-25 | Vanderbilt University | Substituted 1,1,3,1-tetraoxidobenzo[D][1,3,2]dithiazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| MA38885B1 (fr) * | 2013-09-25 | 2018-11-30 | Hoffmann La Roche | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) |
| EP2853532B1 (en) | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| BR112016017816A8 (pt) * | 2014-02-25 | 2020-06-30 | Hoffmann La Roche | derivados de etinila, seus usos, e composição farmacêutica |
| WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123629A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123627A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| EP3271353B1 (en) * | 2015-03-19 | 2019-11-27 | H. Hoffnabb-La Roche Ag | 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4 |
| WO2016179351A1 (en) | 2015-05-05 | 2016-11-10 | Northwestern University | Treatment of levodopa-induced dyskinesias |
| CA2984711C (en) | 2015-07-15 | 2023-08-29 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as metabotropic glutamate receptor modulators |
| CA3030788A1 (en) | 2016-07-18 | 2018-01-25 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11242342B2 (en) | 2016-11-08 | 2022-02-08 | Vanderbilt University | Isoquinoline amine compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP3668865A1 (en) | 2017-08-16 | 2020-06-24 | Vanderbilt University | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| AU2019309448B2 (en) | 2018-07-26 | 2024-08-29 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 |
| CN119504747B (zh) * | 2024-11-26 | 2025-11-21 | 上海交通大学 | 一种含氮杂季碳双环海因类衍生物及其合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK529378A (da) * | 1978-01-09 | 1979-07-10 | Shell Int Research | Anilidderivater |
| TW521073B (en) | 1994-01-05 | 2003-02-21 | Hoechst Marion Roussel Inc | New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them |
| FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
| US6355664B1 (en) | 1997-03-03 | 2002-03-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease |
| USRE38132E1 (en) | 1997-03-03 | 2003-06-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease |
| FR2764889B1 (fr) | 1997-06-20 | 2000-09-01 | Sod Conseils Rech Applic | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| US6809088B2 (en) | 1997-03-24 | 2004-10-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| US6335445B1 (en) | 1997-03-24 | 2002-01-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| AU5486600A (en) | 1999-06-15 | 2001-01-02 | Aventis Pharmaceuticals Products Inc. | Solid phase synthesis of n,n-disubstituted diazacycloalkylcarboxy derivatives |
| WO2001007052A1 (en) | 1999-07-21 | 2001-02-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| US6353013B1 (en) | 1999-07-21 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| MXPA02006134A (es) | 1999-12-21 | 2002-12-13 | Guilford Pharm Inc | Compuestos derivados de hidantoina, composiciones farmaceuticas y metodos de uso de los mismos. |
| US6890915B2 (en) | 2001-05-25 | 2005-05-10 | Bristol-Myers Squibb Pharma Company | Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| WO2003029245A1 (en) | 2001-10-01 | 2003-04-10 | Bristol-Myers Squibb Company | Spiro-hydantoin compounds useful as anti-inflammatory agents |
| US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| MXPA05000813A (es) | 2002-07-31 | 2005-04-19 | Euro Celtique Sa | Compuestos hidrantoina aril sustituidos y su uso como bloqueadores del canal de sodio. |
| US7053112B2 (en) | 2002-09-24 | 2006-05-30 | Schering Aktiengesellschaft | Imidazolidinedione analogs useful as anticoagulants and antithrombotics |
| MXPA05013196A (es) | 2003-07-11 | 2006-03-09 | Elbion Ag | Metodo para tratar o evitar trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa 3 del receptor de benzodiazepina. |
| US20060281803A1 (en) * | 2003-09-23 | 2006-12-14 | Lindsley Craig W | Pyrazole modulators of metabotropic glutamate receptors |
| MY139887A (en) * | 2004-04-02 | 2009-11-30 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same. |
| EP2433943B1 (en) | 2004-07-01 | 2013-09-11 | Daiichi Sankyo Company, Limited | Intermediates for thienopyrazole derivatives having PDE7 inhibitory activity |
| UY29896A1 (es) * | 2005-11-04 | 2007-06-29 | Astrazeneca Ab | Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| TW200927747A (en) | 2007-10-16 | 2009-07-01 | Novartis Ag | Organic compounds |
-
2010
- 2010-09-07 IN IN2580DEN2012 patent/IN2012DN02580A/en unknown
- 2010-09-07 CA CA2773038A patent/CA2773038A1/en not_active Abandoned
- 2010-09-07 EP EP10814634A patent/EP2473055A4/en not_active Withdrawn
- 2010-09-07 AU AU2010289281A patent/AU2010289281A1/en not_active Abandoned
- 2010-09-07 BR BR112012004919A patent/BR112012004919A2/pt not_active IP Right Cessation
- 2010-09-07 WO PCT/US2010/048030 patent/WO2011029104A1/en not_active Ceased
- 2010-09-07 JP JP2012528121A patent/JP2013503909A/ja not_active Withdrawn
- 2010-09-07 RU RU2012114770/13A patent/RU2012114770A/ru not_active Application Discontinuation
- 2010-09-07 CN CN2010800490890A patent/CN102740699A/zh active Pending
- 2010-09-07 SG SG2012015525A patent/SG178999A1/en unknown
- 2010-09-07 US US13/394,309 patent/US8779157B2/en not_active Expired - Fee Related
-
2012
- 2012-03-01 IL IL218426A patent/IL218426A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012004919A2 (pt) | 2019-09-24 |
| WO2011029104A1 (en) | 2011-03-10 |
| AU2010289281A1 (en) | 2012-04-12 |
| RU2012114770A (ru) | 2013-10-10 |
| EP2473055A1 (en) | 2012-07-11 |
| JP2013503909A (ja) | 2013-02-04 |
| CN102740699A (zh) | 2012-10-17 |
| US8779157B2 (en) | 2014-07-15 |
| EP2473055A4 (en) | 2013-02-13 |
| IN2012DN02580A (enExample) | 2015-08-28 |
| US20120245153A1 (en) | 2012-09-27 |
| CA2773038A1 (en) | 2011-03-10 |
| SG178999A1 (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL219297A0 (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL218426A0 (en) | Mglur4 allosteric allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL222854A0 (en) | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL214337A0 (en) | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL219568A0 (en) | Aryl and heteroaryl sulfones, as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
| IL221389A0 (en) | Benzisoxazoles and azabenzisoxazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological-dysfunction | |
| IL221390A0 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, composunds, and methods of treating neurological dysfunction | |
| IL239918A0 (en) | Preparations for the treatment of colitis | |
| EP2523944A4 (en) | COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT | |
| PL2364360T3 (pl) | Antysensowne kompozycje i sposoby ich wytwarzania i stosowania | |
| EP2384198A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES | |
| EP2440220A4 (en) | COMPOSITIONS AND METHOD FOR PREPARING COMPOSITIONS FOR PREVENTING AND TREATING HYPERTENSION | |
| ZA201106577B (en) | Compounds and compositions for cognition-enhancement,methods of making,and methods of treating | |
| IL214455A0 (en) | Methods and compositions for treatment of neovascularization | |
| WO2009129357A9 (en) | Method of treating erectile dysfunction | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| EP2507373A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING VEGF | |
| EP2485738A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF ADIPOSITAS | |
| EP2379637A4 (en) | IMPROVED PROCESSES FOR MAKING STYRENE POLYMER COMPOSITIONS AND METHODS OF USE THEREOF | |
| EP2515652A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
| IL217764A0 (en) | Methods and compositions for treating leukemia | |
| EP2424549A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING UROLITHIASIS AND ASSOCIATED SUFFERINGS | |
| TWI454221B (en) | Composition and method for inhibiting formation of body fat | |
| GB0808730D0 (en) | Compositions and methods for the prevention and treatment of schistosomiasis | |
| GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia |